Neuroendocrinology
Original Paper
Ovine Brain Areas Sensitive to Naloxone-Induced Stimulation of Luteinizing Hormone ReleaseMalven P.V. · Stanisiewski E.P. · Haglof S.A.Department of Animal Sciences, Purdue University, West Lafayette, Ind., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: October 06, 1989
Accepted: April 13, 1990
Published online: April 03, 2008
Issue release date: 1990
Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Abstract
Previous work established that intravenous administration of the opioid receptor antagonist naloxone abruptly increased release of luteinizing hormone (LH) and decreased release of prolactin (PRL) in suckled anestrous ewes and also increased LH release in cyclic luteal ewes. The goal of the present research was to identify brain sites at which local unilateral infusions of naloxone would consistently duplicate the previously noted effects of intravenous naloxone. Intracerebral guide tubes were surgically implanted into the brain of 13 nonpregnant and 16 pregnant ewes at least 4 weeks prior to experimentation. Intracerebral infusion (20–40 µl each through an inner cannula) was performed once daily during postpartum anestrus in suckled fall-lambing ewes and during recurring luteal states of the estrous cycle. Naloxone infusion (n = 142) usually consisted of 50 or 100 µg naloxone, although 5 ewes received 200 and 400 µg per infusion. Control infusions (n = 103) consisted of the vehicle for naloxone (i.e., 0.9% NaCl). Serum concentrations of LH and PRL were quantified at 10-min intervals from 90 min before to 100 min after infusion. Hormone data from individual ewes were grouped for least-squares analysis of variance based upon postmortem neuroanatomical identification of each infusion site. Unilateral intracerebral administration of naloxone consistently induced an increase in LH release within 20 min in the following two neuroanatomical groups: basal forebrain (n = 9 ewes) and chiasmatic area (n = 4 ewes). These naloxone-sensitive brain areas constituted an apparent continuum of tissue sites located as far rostral as ventrolateral septum, diagonal band of Broca and nucleus accumbens and continuing caudally into the preoptic area in and around the organum vasculosum of the lamina terminalis. Brain sites at which the present unilateral infusions of naloxone did not consistently stimulate release of LH included those hypothalamic areas caudal to the preoptic area such as anterior, ventromedial and lateral hypothalamic area including the arcuate nucleus and third ventricle. Therefore, neuroanatomical sites at which local unilateral infusion of naloxone stimulated (i.e., disinhibited) release of LH were very similar to the location of LH-releasing hormone (LHRH) perikarya reported by others for the ovine brain and quite distant from the pituitary gland. Although intravenous naloxone was shown previously to decrease PRL release in suckled anestrous ewes, the present infusion of naloxone did not consistently affect PRL release in such ewes. In summary, local unilateral antagonism of opioid receptors in the vicinity of LHRH perikarya was sufficient to disinhibit release of LHRH/LH, but opioid mechanisms stimulatory to PRL release were not antagonized by intracerebral infusions of naloxone.
© 1990 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: October 06, 1989
Accepted: April 13, 1990
Published online: April 03, 2008
Issue release date: 1990
Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
